{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:08:07Z","timestamp":1789751287789,"version":"4.0.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2S","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1097\/tp.0000000000001777","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T14:39:08Z","timestamp":1516891148000},"page":"S50-S59","source":"Crossref","is-referenced-by-count":68,"title":["The Role of mTOR Inhibitors in the Management of Viral Infections"],"prefix":"10.1097","volume":"102","author":[{"given":"Lyndsey J.","family":"Bowman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Brueckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina T.","family":"Doligalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.idc.2010.01.005","article-title":"Infection in organ transplantation: risk factors and evolving patterns of infection","volume":"24","author":"Fishman","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rmv.1733","article-title":"Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms","volume":"23","author":"Brennan","year":"2013","journal-title":"Rev Med Virol"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/TP.0b013e318276a1ef","article-title":"Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients","volume":"95","author":"Havenith","year":"2013","journal-title":"Transplantation"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1600-6143.2011.03473.x","article-title":"Paradoxical aspects of rapamycin immunobiology in transplantation","volume":"11","author":"Ferrer","year":"2011","journal-title":"Am J Transplant"},{"key":"R6-11-20210129","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1600-6143.2012.04002.x","article-title":"CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages","volume":"12","author":"Poglitsch","year":"2012","journal-title":"Am J Transplant"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/AAC.46.11.3447-3455.2002","article-title":"The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication","volume":"46","author":"Roy","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis","volume":"94","author":"Andrassy","year":"2012","journal-title":"Transplantation"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1111\/j.1432-2277.2012.01489.x","article-title":"Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors","volume":"25","author":"Sab\u00e9","year":"2012","journal-title":"Transpl Int"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/tid.12007","article-title":"Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation","volume":"15","author":"Kobashigawa","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.healun.2013.04.010","article-title":"Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation","volume":"32","author":"Ghassemieh","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.transproceed.2014.11.026","article-title":"Effect of early conversion to everolimus together with prophylaxis with valganciclovir in the prevention of cytomegalovirus infection in heart transplant recipients","volume":"47","author":"D\u00edaz Molina","year":"2015","journal-title":"Transplant Proc"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2014.10.016","article-title":"Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection","volume":"113","author":"Ritt\u00e0","year":"2015","journal-title":"Antiviral Res"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jcv.2015.04.017","article-title":"Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: a single centre, prospective cohort study","volume":"68","author":"Durante-Mangoni","year":"2015","journal-title":"J Clin Virol"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/tri.12848","article-title":"Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis","volume":"29","author":"Cervera","year":"2016","journal-title":"Transpl Int"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/TP.0b013e31825a505d","article-title":"Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation","volume":"94","author":"Schwarz","year":"2012","journal-title":"Transplantation"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ctr.12151","article-title":"Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience","volume":"27","author":"Moscarelli","year":"2013","journal-title":"Clin Transplant"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2369-14-207","article-title":"BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition","volume":"14","author":"Jacobi","year":"2013","journal-title":"BMC Nephrol"},{"key":"R20-11-20210129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.transproceed.2014.11.008","article-title":"Everolimus-based immunosuppression therapy for BK virus nephropathy","volume":"47","author":"Polanco","year":"2015","journal-title":"Transplant Proc"},{"key":"R21-11-20210129","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1600-6143.2011.03767.x","article-title":"Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression","volume":"11","author":"McKenna","year":"2011","journal-title":"Am J Transplant"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1016\/j.transproceed.2013.04.011","article-title":"Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience","volume":"45","author":"Kelly","year":"2013","journal-title":"Transplant Proc"},{"key":"R23-11-20210129","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/liv.12416","article-title":"Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors","volume":"34","author":"Villamil","year":"2014","journal-title":"Liver Int"},{"key":"R24-11-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/TP.0b013e31823ae7db","article-title":"Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients","volume":"93","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"R25-11-20210129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1155\/2015\/517359","article-title":"Post-transplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations","volume":"29","author":"Mumtaz","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R26-11-20210129","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/TP.0b013e3181c7dcc0","article-title":"First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation","volume":"89","author":"Di Benedetto","year":"2010","journal-title":"Transplantation"},{"key":"R28-11-20210129","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1016\/j.transproceed.2012.09.025","article-title":"Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases","volume":"44","author":"Yaich","year":"2012","journal-title":"Transplant Proc"},{"key":"R29-11-20210129","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/ajt.12699","article-title":"Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients","volume":"14","author":"Stock","year":"2014","journal-title":"Am J Transplant"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"R31-11-20210129","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1111\/j.1600-6143.2009.02904.x","article-title":"BK virus in solid organ transplant recipients","volume":"9","author":"Hirsch","year":"2009","journal-title":"Am J Transplant"},{"key":"R32-11-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.trre.2015.02.004","article-title":"The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: a systematic review","volume":"29","author":"Viswesh","year":"2015","journal-title":"Transplant Rev (Orlando"},{"key":"R33-11-20210129","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.intimp.2010.05.006","article-title":"Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates","volume":"10","author":"Wagner","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"R34-11-20210129","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jhep.2011.06.031","article-title":"Immunosuppression and HCV recurrence after liver transplantation","volume":"56","author":"Samonakis","year":"2012","journal-title":"J Hepatol"},{"key":"R35-11-20210129","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1158\/1078-0432.CCR-13-3172","article-title":"mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells","volume":"20","author":"Kawada","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R36-11-20210129","doi-asserted-by":"crossref","first-page":"F343","DOI":"10.1152\/ajprenal.00135.2013","article-title":"mTOR plays a critical role in p53-induced oxidative kidney cell injury in HIVAN","volume":"305","author":"Rai","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"R37-11-20210129","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa1001197","article-title":"Outcomes of kidney transplantation in HIV-infected recipients","volume":"363","author":"Stock","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:28:39Z","timestamp":1620977319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201802001-00011"}},"subtitle":["A Review of Current Literature"],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":37,"journal-issue":{"issue":"2S","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001777","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}